Specialty Oncology
-
Featured
Tracking Outcomes in Proton Therapy for Cancer
Massachusetts General Hospital clinician-researchers work to define which patients can benefit most from advanced proton therapy for cancer.
-
Featured
Overcoming Barriers to Lung Cancer Screening
Lung cancer screening is an extremely underused tool. Review the lung cancer screening guidelines with the American Lung Cancer Screening Initiative's founder, Chi-Fu Jeffrey Yang, MD, of Massachusetts General Hospital.
-
Less Aggressive Protocol Suitable for Muscle-invasive Bladder Cancer in Noncystectomy Candidates
Douglas M. Dahl, MD, Jason A. Efstathiou, MD, DPhil, and colleagues determined that in patients with muscle-invasive bladder cancer who were not candidates for cystectomy or cisplatin, maximum tumor resection and chemoradiation were associated with high response rates and five-year overall survival rates of 25% to 38%.
-
Comprehensive Lymphadenectomy Often Not Necessary in Surgical Management of Primary Endometrioid Ovarian Carcinoma
Varvara Mazina, MD, Marcela G. del Carmen, MD, MPH, and colleagues showed in a retrospective cohort of 63 women with primary endometrioid ovarian cancer that all pelvic and para-aortic lymph nodes removed were negative for carcinoma and comprehensive cancer staging had no effect on progression-free or overall survival.
-
Vitamin C Might Have Clinical Benefit Against KRAS- and BRAF-mutated CRC
Shuji Ogino, MD, PhD, Mingyang Song, MBBS, ScD, and colleagues leveraged data from two large, prospective U.S. studies that showed the use of vitamin C after diagnosis of colorectal cancer with KRAS or BRAF mutations was associated with a 26% reduction in the risk of disease-specific mortality.
-
Developing a Personalized Approach for Targeted Radiotherapy of Liver Cancers
Researchers at Massachusetts General Hospital are developing computation models capable of increasing the precision of targeted delivery of radiotherapy to liver tumors.
Mass General Cancer Center Contributors
-
Andrew T. Chan, MD, MPH
Daniel K. Podolsky Professor of Medicine, Harvard Medical School, Director for Cancer Epidemiology, Mass General Cancer Center, Chief, Clinical and Translational Epidemiology Unit, Department of Medicine
Recent Article
PPI, H2RA Use by Older Adults Not Associated With Dementia or Cognitive Impairment -
Areej R. El-Jawahri, MD
Hematologist, Mass General Cancer Center, Assistant in Medicine, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School
Recent Article
Enasidenib Safe, Well Tolerated As Maintenance After Stem Cell Transplantation for IDH2-Mutated Myeloid Malignancies -
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Combined Standard and Targeted Transperineal Biopsies Advised for Patients With Prostate Lesion on Multiparametric MRI -
Keith T. Flaherty, MD
Director of Clinical Research, Mass General Cancer Center, Professor of Medicine, Harvard Medical School
Recent Article
37 Biopsies, Nine Years: Mapping Evolution of Resistance to Melanoma Immunotherapy in a Former Complete Responder -
Keyan Salari, MD, PhD
Director of Translational Research, Urologic Surgeon, Department of Urology, Massachusetts General Hospital, Director, Prostate Cancer Genetics Program, Mass General Cancer Center, Assistant Professor of Surgery, Harvard Medical School
Recent Article
Urine Test Validated for Diagnosis, Surveillance and Risk Prediction in Urothelial Carcinoma -
Marcela G. del Carmen, MD, MPH
President, Massachusetts General Physicians Organization, Gynecologic Oncologist, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Executive Vice President, Mass General Brigham
Recent Article
Comprehensive Lymphadenectomy Often Not Necessary in Surgical Management of Primary Endometrioid Ovarian Carcinoma -
Marcela V. Maus, MD, PhD
Director, Cellular Immunotherapy Program, Mass General Cancer Center, Associate Professor of Medicine, Harvard Medical School
Recent Article
Novel Tandem CAR T-Cell Effective Against Heterogeneous Glioblastoma -
Nir Hacohen, PhD
Director, MGH Center for Cancer Immunology
Center for Cancer Research , Professor of Medicine, Harvard Medical School, Senior Member, Broad InstituteRecent Article
Considering Both Tumor and Immune Features May Improve Prediction of Melanoma Outcomes After Checkpoint Inhibition -
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology, Massachusetts General Hospital, Adeline Rose Wydotis Professor of Neurosurgery, Harvard Medical School
Recent Article
Review: The Role of Antibody-Based Therapies in Neuro-Oncology